Streptozocin (Synonyms: Estreptozocin, NSC 37917, NSC 85998, Streptozocin, STZ, U 9889) |
| Catalog No.GC17131 |
Un agente diabetogénico que se dirige a las células beta.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 18883-66-4
Sample solution is provided at 25 µL, 10mM.
Streptozocin, a potent DNA-methylating antibiotic, is a naturally occurring nitrosoamide used for extensively to produce diabetes in experimental models.[1]
In vitro, STZ was toxic with IC50 values of 11.7, 904 and 1024 μg/ml for HL60, K562 and C1498 cells respectively.[3]
In vivo efficacy test it shown that when combined with a protocol for induction of diuresis, dogs were treated safely with 500 mg/m2 of streptozocin, intravenously, every 3 weeks, and it may be have a potential efficacy on the treatment of dogs with metastatic pancreatic islet cell tumors.[1]
In vivo experiment it indicated that mice were administrated streptozocin with 65 mg/kg intraperitoneally for 8-11 days or 14-17 days, streptozocin improved the impaired development of preimplantation embryos on 8-11 days. However, after 14-17 days, the incidence of degenerated embryos was increased in both streptozocin-treated mice groups.[2] Treatment with 60 mg/kg of streptozocin intravenously also induces an early hyperglycaemia when the hepatic glycogen storage is almost depleted that is during the fasting state.[4] For the treatment of advanced islet-cell carcinoma, the combination of streptozocin and doxorubicin is more efficious than the current standard regimen of streptozocin plus fluorouracil.[5] There is little value for patients with malignant carcinoid tumors by combination treatment with streptozocin and 5-fluorouracil.[6]
References:
[1].Moore AS, et al. Streptozocin for treatment of pancreatic islet cell tumors in dogs: 17 cases (1989-1999). J Am Vet Med Assoc. 2002 Sep 15;221(6):811-8.
[2].Veselá J, et al. Subdiabetogenic streptozocin treatment impairs preimplantation development of mouse embryos. Physiol Res. 1993;42(1):23-7.
[3].Diab RA, et al. Immunotoxicological effects of streptozotocin and alloxan: in vitro and in vivo studies. Immunol Lett. 2015 Feb;163(2):193-8.
[4].Wong KK. Reduction by streptozocin of blood glucose utilization during the appearance of the streptozocin induced early hyperglycaemia in fasting rats. Biochem Mol Biol Int. 1996 May;39(1):191-5.
[5].Moertel CG, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992 Feb 20;326(8):519-23.
[6].Oberg K, et al. Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin--alone or in combination with 5-FU. Acta Oncol. 1987;26(6):429-32.
| Cell experiment [1]: | |
|
Cell lines |
islet cells |
|
Preparation Method |
Monolayer cultures of islet cells from neonatal rats were exposed to concentrations of MNU and STZ (Streptozocin) of 1, 2, 5, or 10 mM, and the activity of the enzyme was assayed. |
|
Reaction Conditions |
1, 2, 5, or 10 mM |
|
Applications |
Streptozocin is toxic to cultured p-cells at a concentration of 1 mM. |
| Animal experiment [2]: | |
|
Animal models |
Female mice |
|
Preparation Method |
Female mice received a single subdiabetogenic dose of streptozocin (65 mg/kg intraperitoneally) 8-11 days or 14-17 days before fertilization. |
|
Dosage form |
65 mg/kg; i.p. |
|
Applications |
Morphological analysis of preimplantation embryos collected on day 3 of pregnancy revealed significant changes in the distribution pattern of preimplantation embryo stages recovered from streptozocin-treated females. |
|
References: [1]. Wilson GL, et al. Mechanisms of nitrosourea-induced beta-cell damage. Activation of poly (ADP-ribose) synthetase and cellular distribution. Diabetes. 1988 Feb;37(2):213-6. [2]. Veselá J, et al. Subdiabetogenic streptozocin treatment impairs preimplantation development of mouse embryos. Physiol Res. 1993;42(1):23-7. |
|
| Cas No. | 18883-66-4 | SDF | |
| Sinónimos | Estreptozocin, NSC 37917, NSC 85998, Streptozocin, STZ, U 9889 | ||
| Chemical Name | 1-methyl-1-nitroso-3-[2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea | ||
| Canonical SMILES | CN(C(=O)NC1C(C(C(OC1O)CO)O)O)N=O | ||
| Formula | C8H15N3O7 | M.Wt | 265.22 |
| Solubility | ≥ 10.3mg/mL in DMSO, ≥ 53.2mg/mL in Water, ≥ 26.5mg/mL in EtOH with gentle warming | Storage | -20°C, protect from light, stored under nitrogen,unstable in solution, ready to use. |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7705 mL | 18.8523 mL | 37.7045 mL |
| 5 mM | 0.7541 mL | 3.7705 mL | 7.5409 mL |
| 10 mM | 0.377 mL | 1.8852 mL | 3.7705 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *